

CINP's Hanns Hippius International Psychopharmacology Archives at the Psychiatry  
Clinic of Ludwig Maximilian University in Munich

Collated by Peter Kadar

### **6(3). Contributions to the Archives**

#### **Thomas A. Ban: Psychopharmacology and the First Fifty years in History of the CINP (PowerPoint presentation)**

PowerPoint presentation at CINP's 50<sup>th</sup> Anniversary meeting held from  
July 13 to 17, 2008 in Munich, September 26, 2013.




**Bernard (Steve) Brodie**



**Alfred Pletscher**

**National Heart Institute USA**

**Reserpine and iproniazid have opposite effects on brain  
serotonin levels and in some patients on mood**



**Wolfgang de Boor**                      **Corneille Radouco-Thomas**  
**Proposed at first international congress on Psychotropic Drugs**  
**(Milan, May 1957) the founding of the CINP**



**Ernst Rothlin**  
**Former Director of Sandoz**  
**Founding President**  
**September 2, 1957**



**Hanns Hippus**  
German psychiatrist




**Cornelis C. Van Rhy**  
Dutch psychiatrist

**Two of the 32 founders of the CINP**



**Emilio Trabucchi**  
Professor of Pharmacology  
Purpose: Education




**Ernst Rothlin**  
Former Director of Sandoz  
Purpose: Research

**1958-1964****First Four Congresses**

**Ernst Rothlin**    **Ernst Rothlin**    **Paul Hoch**    **Hans Hoff**  
**1<sup>st</sup> Rome 1958**    **2<sup>nd</sup> Basel 1960**    **3<sup>rd</sup> Munich 1962**    **4<sup>th</sup> Birmingham 1964**

**ISSUES AT THE HEART OF NEUROPSYCHOPHARMACOLGY:**


- \* **Relevance of “model psychoses” to naturally occurring psychoses**
- \* **Mode of action of drugs with known therapeutic effects**
- \* **Translation of findings from animal to man**
- \* **Relevance of mode of action of drugs to pathophysiology of psychoses**



**Arvid Carlsson**

**Swedish pharmacologist**

**Selective changes in brain monoamines with psychotropic drugs  
Influenced psychotropic drug development to date**



**Joseph Schildkraut**  
 American psychiatrist  
 Catecholamine hypothesis  
 affective disorders (1965)



**Jacques Van Rossum**  
 Dutch pharmacologist  
 Dopamine hypothesis  
 schizophrenia (1966)

### 1966-1968

**Jean Delay**  
 5<sup>th</sup> Washington 1966

**Francisco Valdecasas**  
 6<sup>th</sup> Tarragona 1968

### PHARMACOLOGICAL HETEROGENEITY WITHIN DIAGNOSES:

- \* Precluded the generation of information about pathophysiology (biochemical underpning) of mental disorders
- \* Delayed acceptance of psychotropic drugs for clinical use

## 1970-1978

<b>Lehmann</b> 7 <sup>th</sup> Prague 1970	<b>Jacobssen</b> 8 <sup>th</sup> Copenhagen 1972	<b>Hippius</b> 9 <sup>th</sup> Paris 1974	<b>Deniker</b> 10 <sup>th</sup> Quebec 1976	<b>Hollister</b> 11 <sup>th</sup> Vienna 1978
--	--	---	---	---

## DURING THE 1970s

Psychotropic drugs became primary form of treatment

## 1980-1984

<b>Arvid Carlsson</b> 12 <sup>th</sup> Goteborg 1980	<b>Paul Janssen</b> 13 <sup>th</sup> Jerusalem 1982	<b>Paul Kielholz</b> 14 <sup>th</sup> Florence 1984
---	--	--

## IN THE EARLY 1980s

- \* Neuropharmacological research extended from neurochemistry at synaptic cleft to receptor bindings
- \* Clinical methodology remained restricted to demonstrating therapeutic efficacy
- \* The gap grew so wide that it required the translation of findings that their clinical relevance could be understood

## TRAINING OF NEW CADRES OF NEUROPSYCHOPHARMACOLOGISTS (1984-)

PERIOD	PRESIDENT	CONGRESS	DEVELOPMENT
1984-1986	Ole Rafaelsen	San Juan	Logo
1986-1988	William Bunney	Munich	Travel Awards
1988-1990	Alec Coppen	Kyoto	Presidents' Workshop
1990-1992	Julien Mendlewicz	Nice	1 <sup>st</sup> Presidents' Workshop
1992-1994	Giogio Racagni	Washington	Regional meeting
1994-1996	Lewis Judd	Melbourne	1 <sup>st</sup> Regional meeting
1996-1998	Claude de Montigny	Glasgow	Pioneer award
1998-2000	Helmut Beckmann	Brussels	Incorporation: July 26, 1999
2000-2002	Eugene Paykel	Montreal	Regionalization
2002-2004	Herbert Meltzer	Paris	Opening Central Office



**Brian Leonard**  
President  
2004-2006  
Amendment of Constitution  
to include training programs




**Norman Sartorius**  
Chairman  
Antidepressant Task Force  
Worldwide forum  
to discuss recommendations



**Ole Rafaelsen**




**Hanns Hippius**



**Thomas Ban**

**The history committee began in 1986 as a working collaboration.**




**Torgny Svensson  
President  
2006-2008**


**Extension of educational activities  
Completion of administrative structure**

**CENTRAL THEME IN DEBATE**  
(antidepressant task force report)

**A review of evidence based findings generated in multi-center clinical studies designed with power statistics with the employment of consensus based diagnoses and sensitized rating scales could lead to wrong conclusions about the optimal use of antidepressants.**



**Fritz Freyhan**  
**1956**  
**Pharmacological re-evaluation of**  
**psychiatric nosology needed**



**Donald Klein**  
**2008**  
**Pharmacological dissection**  
**sabotaged**



**Robert Belmaker  
President elect**

## **THE CINP'S ACHIEVEMENTS IN FIRST 50 YEARS**

**Grown into a powerful organization.**

**Membership grew to 1100 from 52 countries**

**Transformation of thinking in psychiatry from  
psychological to biological**

## **ENTERING NEW ERA**

**To continue on the road to becoming the world's most influential organization in the education of pharmacotherapy with psychotropic drugs.**

**&**

**To encourage scientific study in order to identify pharmacologically homogeneous populations that would make possible the generation of information on the pathophysiology (biochemical underpinning) of mental illness by studying the mode of action of psychotropic drugs.**



**Ernst Rothlin  
Founding President**

**Saw the CINP as a unique organization that will guide( pharmaceutical industry in developing increasingly more (selective and) effective drugs for mental illness.**

April 22, 2021